Mainsail Asset Management LLC Makes New $2.38 Million Investment in Danaher Corporation $DHR

Mainsail Asset Management LLC acquired a new position in Danaher Corporation (NYSE:DHR) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,742 shares of the conglomerate’s stock, valued at approximately $2,380,000. Danaher makes up 1.0% of Mainsail Asset Management LLC’s portfolio, making the stock its 17th biggest holding.

A number of other hedge funds and other institutional investors also recently bought and sold shares of DHR. BlackRock Inc. purchased a new stake in shares of Danaher during the 2nd quarter worth $10,492,520,000. Wellington Management Group LLP grew its stake in shares of Danaher by 10.4% during the 2nd quarter. Wellington Management Group LLP now owns 16,316,834 shares of the conglomerate’s stock worth $3,108,031,000 after purchasing an additional 1,542,310 shares during the period. Jupiter Topco LLC purchased a new position in shares of Danaher in the 2nd quarter valued at about $1,456,317,000. Generation Investment Management LLP purchased a new position in shares of Danaher in the 2nd quarter valued at about $1,287,949,000. Finally, Bank of America Corp DE acquired a new stake in shares of Danaher in the second quarter valued at about $993,846,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on DHR shares. Evercore reissued an “outperform” rating and set a $230.00 price objective on shares of Danaher in a report on Monday, July 6th. UBS Group started coverage on shares of Danaher in a research report on Wednesday, September 9th. They set a “buy” rating and a $250.00 target price on the stock. Wall Street Zen raised shares of Danaher from a “hold” rating to a “buy” rating in a report on Saturday, October 10th. The Goldman Sachs Group lifted their price target on shares of Danaher from $210.00 to $250.00 and gave the company a “buy” rating in a research report on Monday, September 21st. Finally, TD Cowen boosted their price target on Danaher from $236.00 to $255.00 and gave the stock a “buy” rating in a research note on Tuesday. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, Danaher presently has an average rating of “Moderate Buy” and a consensus price target of $235.41.

Danaher Stock Up 0.8%

Danaher stock opened at $224.65 on Thursday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. The firm has a market capitalization of $157.93 billion, a price-to-earnings ratio of 39.90, a price-to-earnings-growth ratio of 2.80 and a beta of 0.76. Danaher Corporation has a fifty-two week low of $160.93 and a fifty-two week high of $242.80. The stock’s fifty day moving average is $212.92 and its two-hundred day moving average is $195.39.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. The business had revenue of $6.26 billion during the quarter, compared to analysts’ expectations of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%. The business’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same quarter last year, the business posted $0.77 earnings per share. Analysts predict that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 0.7%. The ex-dividend date is Wednesday, September 30th. Danaher’s dividend payout ratio (DPR) is 28.42%.

Key Stories Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: AI partnership with NVIDIA: Danaher announced a collaboration to combine its scientific instruments, laboratory automation, workflow software and industry expertise with NVIDIA’s accelerated computing and AI technologies. The initiative is intended to advance autonomous science and speed scientific discovery, supporting Danaher’s long-term growth outlook in life-science tools and laboratory automation. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Potential earnings beat: Zacks reports that Danaher has a strong history of exceeding quarterly estimates and currently has favorable Earnings ESP and consensus-estimate trends, raising expectations for another beat in its upcoming report. The company previously exceeded estimates with quarterly earnings of $1.94 per share versus a $1.85 consensus, while revenue rose 5.5% year over year. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: Longer-term automation opportunity: Danaher’s planned AI-powered autonomous laboratory, targeted for commercial-scale operation in early 2027, gives investors a potential future growth catalyst. The NVIDIA relationship could strengthen Danaher’s position as laboratories adopt AI and physical automation. How to Invest in AI Drug Discovery
• Neutral Sentiment: Analyst support: Morgan Stanley maintained a $240 price target, implying continued confidence in Danaher’s prospects, although the unchanged target provides no new upgrade catalyst. Morgan Stanley Keeps $240 Target for Danaher Stock
• Neutral Sentiment: Board changes: Danaher expanded its board to 13 members and appointed new directors, a governance development with limited immediate earnings or valuation impact. Danaher Enhances Board With New Director Appointments

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.